Wikipedia -WSS

Wikipedia

author：comprehensive 2025-10-01 00:59:05 - browse：69494

Adobe

WASHINGTON — WuXi Biologics executives have joined the lobbying fray in the lead-up to a move by Congress to add the company to a blacklist meant to prevent certain biotech firms from doing business in the United States.

Legislation proposing that blacklist, known as the BIOSECURE Act, was passed in a 40-1 bipartisan vote on Wednesday by the House Oversight and Accountability Committee. That’s an important development because until now, the House Select Committee on the Chinese Communist Party had handled the bill in the House. That panel is an ad-hoc committee created to build bipartisan consensus on China policies, but it does not have the authority to pass legislation. A Senate committee also passed the BIOSECURE Act nearly unanimously earlier this year.

With the bill out of the Oversight Committee, the goal is for the House to pass it before the July 4 recess. That would set the legislation up to be included in a year-end must-pass legislative package, possibly the National Defense Authorization Act, which Congress has passed every year for decades.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： ASCO: AstraZeneca's hat trick, and palliative care's spotlight

WSS

See how much Covid

California store owner shot dead in dispute over displaying Pride flag: Police

Listen: Vivek Ramaswamy's star turn & leaky drug data

Shifting the focus from loneliness to social health

With trial win, GSK could get blood cancer drug back on market

Health officials lay out plans to cope with respiratory virus season

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

Heart attack and stroke risk calculators need revising

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

United colonoscopy coverage change 'may cost lives,' doctors say

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Peter Hotez and the public health issue of online harassment

PBMs are inflating the cost of generic drugs. They must be reined in

Medical records are filled with copy

Wegovy improves function in certain heart failure patients

Cancer drug shortages should be causing more outrage

Can U.S. cancer drug shortages be fixed?

hotspot

Cord blood banking comes at a high cost to babies

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Letters to First Opinion on caregivers, digital health, and more

Listen: Vivek Ramaswamy's star turn & leaky drug data

Change Healthcare can notify patients about the breach, HHS says

ASCO: Palliative care found as helpful given virtually as in person

knowledge

hotspot

focus

knowledge